HÄMOGLOBINZUSAMMENSETZUNGEN

European patent · EP3266463 · In force

Register entry

Publication number
EP3266463
Application number
EP17188857
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 9, 2010
Published
Jan 10, 2018
Granted
Dec 13, 2023
Protection ends at the latest
Jun 8, 2030
Next annual fee due
Jun 30, 2027
IPC classes
A61K 38/42 (2006.01)
A61K 9/00 (2006.01)
A61K 9/08 (2006.01)
A61K 47/02 (2006.01)
A61K 47/60 (2017.01)
A61P 9/10 (2006.01)
A61P 7/00 (2006.01)
A61P 7/06 (2006.01)
A61P 7/08 (2006.01)
A61P 9/00 (2006.01)
A61P 17/02 (2006.01)
A61P 35/00 (2006.01)
A61P 39/06 (2006.01)
Priority
US 185547 P 09.06.2009
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Jul 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 01.07.2025

  3. Oct 23, 2024

    Change

    Published in Swissreg on 23.10.2024

  4. Jul 1, 2024

    Change

    Published in Swissreg on 01.07.2024

  5. Jan 16, 2024

    Agent entered

    Representative
    MICHELI & CIE SA, 122, rue de Genève,, CP 61, 1226 Thônex

    Published in Swissreg on 16.01.2024

  6. Dec 13, 2023

    Granted

    Published in Swissreg on 13.12.2023

Parties

Holder

Prolong Pharmaceuticals, LLC

300 Corporate Court Suite B, South Plainfield, NJ 07080, US

Agent

MICHELI & CIE SA

122, rue de Genève, CP 61, 1226 Thônex

Inventor

ABUCHOWSKI, Abraham

California, NJ 07830, US

SLOSHBERG, Steven

Union, NJ 07083, US

O'HARE, Keith

East Windsor, NJ 08520, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.